Research: Can newly-public biotech succeed at translational science? by Laura McNamee and Fred Ledley

Early-stage biotech companies play a critical role in the entrepreneurial ecosystem that is expected to develop commercial products from nascent scientific discoveries. Recent research from the Center for Integration of Science and Industry suggests that companies in the IPO “class of 2000” were ineffective in developing therapeutic products and asks whether the business models of newly-public biotech companies are up to the task.

Sticky Post: